Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis
-
Published:2020-05-05
Issue:1
Volume:123
Page:33-37
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Eggemann Holm,Brucker Cosima,Schrauder Michael,Thill Marc,Flock Felix,Reinisch Mattea,Costa Serban-Dan,Ignatov Atanas
Abstract
Abstract
Background
Due to the lack of prospective data, current treatment of male breast cancer (MBC) is based on information obtained from retrospective analysis or by extrapolation from studies on female patients. In this prospectively enrolled cohort study, we retrospectively examined the survival effect of tamoxifen in MBC patients.
Methods
In this prospectively enrolled cohort study, 448 patients with MBC were treated between May 2009 and June 2018. The primary endpoint was disease-free survival (DFS).
Results
Between May 2009 and June 2018, 448 men with breast cancer were identified, with a median age at diagnosis of 69 years (range 27–96 years). The median follow-up was 39 months (range 3–89 months). Most tumours were larger than 20 mm; invasive ductal carcinoma was of no special histological type and with an intermediate grade of differentiation. Almost half of the men were diagnosed with positive axillary lymph nodes (43.5%). Hormone receptor (HR) positivity was observed in 98.4% of the patients. Notably, DFS among men who did not receive tamoxifen was significantly reduced as compared with those who underwent tamoxifen therapy (P = 0.002). The recurrence rate and mortality in the group of patients without and with tamoxifen treatment were 18.2% and 11.2%, respectively. The most common localisation of metastases was the bone. After adjustment for prognostic factors, we found that tamoxifen was found to reduce the recurrence rate by 68% (hazard ratio HR = 0.32; 95% confidence interval, CI: 0.14–0.74).
Conclusions
Tamoxifen treatment was associated with improved DFS for MBC patients.
Clinical trial registration
DRKS00009536.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference16 articles.
1. Losurdo, A., Rota, S., Gullo, G., Masci, G., Torrisi, R., Bottai, G. et al. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: a review of the literature. Crit. Rev. Oncol. Hematol. 113, 283–291 (2017). 2. Leon-Ferre, R. A., Giridhar, K. V., Hieken, T. J., Mutter, R. W., Couch, F. J., Jimenez, R. E. et al. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis 37, 599–614 (2018). 3. Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Rohl, F. W. et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res. Treat. 137, 465–470 (2013). 4. Streng, M., Ignatov, A., Reinisch, M., Costa, S. D. & Eggemann, H. A comparison of tumour size measurements with palpation, ultrasound and mammography in male breast cancer: first results of the prospective register study. J. Cancer Res. Clin. Oncol. 144, 381–387 (2018). 5. Eggemann, H., Altmann, U., Costa, S. D. & Ignatov, A. Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. J. Cancer Res. Clin. Oncol. 144, 337–341 (2017).
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|